 Ardelyx Inc saw its value soar today after the US Food and Drug Administrations FDA advisory panel recommended the approval of the groups drug for chronic kidney disease patients on dialysis, more than a year after it was initially rejected. The panel voted 9-4 in favor of the drug, Xphozah tenapanor, to be administered as a single therapy for treating high phosphate levels in the blood of patients on dialysis. 